Zepbound vs Mounjaro: Same Drug, Very Different Price

The question comes up constantly: what's the difference between Zepbound and Mounjaro?

The short answer is: the drug is identical. Both are tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Same molecule, same mechanism, same doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg), same manufacturing facility.

The difference is the indication — and price.

Why There Are Two Brand Names

FDA approval creates separate product approvals for separate indications. Eli Lilly first got tirzepatide approved as Mounjaro for type 2 diabetes management in 2022. Two years later, they got it approved as Zepbound for chronic weight management in adults with obesity or overweight with a weight-related condition.

Same drug. Two approvals. Two packages. Two prices.

This is common in pharma — you'll see the same pattern with duloxetine (Cymbalta for depression, Drizalma for pain), or buproprion (Wellbutrin for depression, Zyban for smoking cessation).

What's Actually Different

The indication on the label. Mounjaro is labeled for type 2 diabetes. Zepbound is labeled for obesity/weight management.

The pen design. Zepbound uses a single-dose vial system for some doses, while Mounjaro uses autoinjector pens. Both are self-administered subcutaneously.

Insurance coverage pathways. This is the biggest practical difference. If you have type 2 diabetes, your insurance may cover Mounjaro as a diabetes medication. If you're using it for weight loss only, Zepbound is the on-label choice — but most insurance doesn't cover GLP-1s for weight loss.

List price. Both carry a list price around $1,000-$1,100/month without insurance.

The Off-Label Reality

Here's what most coverage doesn't mention: physicians commonly prescribe Mounjaro off-label for weight loss, even for patients without diabetes. If the prescriber writes for Mounjaro and you have diabetes or prediabetes, coverage is more likely. For purely weight-loss patients without a diabetes diagnosis, Zepbound is the cleaner choice on paper.

In practice, the drugs are interchangeable, and many patients have gotten better pricing through one brand versus the other depending on their insurer and plan.

What to Do If You Can't Afford Either

Brand tirzepatide at $1,000+/month is out of reach for most people paying out of pocket. The alternatives:

Compounded tirzepatide: While the FDA shortage designation for tirzepatide has been complicated (the agency declared shortage resolution in 2025, which affected compounders' ability to legally compound it), some compounding pharmacies continue to operate. The legal landscape has shifted — check with a telehealth provider for current status.

Savings programs: Eli Lilly has run savings programs (at times dropping cost to ~$25/month with commercial insurance, or ~$550/month uninsured). These programs change frequently — verify current availability.

Comparing to semaglutide: If tirzepatide cost is prohibitive, compounded semaglutide typically runs $200-400/month at telehealth platforms like Marrow and remains more widely available through compounding pharmacies.

Which Should You Ask For?

If you have type 2 diabetes: Mounjaro may have better insurance coverage.

If you're using it for weight loss only and have commercial insurance: Ask your prescriber whether Zepbound coverage is better on your plan.

If you're paying out of pocket: The drug is the same — get whichever your prescriber writes. Alternatively, explore compounded semaglutide or tirzepatide through a telehealth platform, which can dramatically reduce cost.

The bottom line: don't get distracted by the brand name debate. The molecule is identical. What matters is access, cost, and finding a prescriber who can navigate the options with you.